NasdaqGS:INBXBiotechs
A Look At Inhibrx Biosciences (INBX) Valuation After HexAgon Phase 2 Data And Phase 3 Plans
Inhibrx Biosciences (INBX) has become a focus for biotech investors after reporting interim Phase 2 HexAgon data on INBRX-106 combined with pembrolizumab in first-line head and neck cancer, alongside a recent first quarter earnings update.
See our latest analysis for Inhibrx Biosciences.
The interim HexAgon data and first quarter earnings update come after a period of strong market interest, with a 30 day share price return of 24.12% and a year to date share price return of 45.94%. The 1 year...